Page 3 - Cell Surface News Today

Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...

Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapyTotal patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 perce...

Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell

Press release content from Business Wire. The AP news staff was not involved in its creation.

(2022-05-26 | NDAQ:GMAB) Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple epcoritamab (DuoBody-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line

Lineup to include Horton Foote’s ‘The Trip to Bountiful' and Cheryl L. West’s new musical about rock ‘n’ roll trailblazer Sister Rosetta Tharpe.

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

Multiple epcoritamab (DuoBody-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several

Company AnnouncementBased on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial to be presented at a future medical meetingLarge B-cell lymphoma (LBCL) is a common form of non-Hodgkin’s lymphoma (NHL...